- Cancer Types
Information about risk, prevention, screening, symptoms, diagnosis, treatment, and support for all cancers Cancer A to Z - Cancer Treatment
Cancer Treatment
Information about cancer treatment, including surgery, chemotherapy, radiation therapy, clinical trials, proton therapy, complementary medicine, and cutting edge technologies.
- Risk and Prevention
- Cancer Drugs
- Support
Support
Ways for cancer patients and caregivers to cope with cancer, side effects, nutrition, general cancer support issues, grief/end of life issues, and shared survivor's experiences.
- Healthcare Professionals
- Clinical Trials
My Patient Treatment Binder
OncoLink Blogs
What's My Cancer Risk?
OncoPilot: Navigating Your Cancer Journey
Community Events Calendar
OncoLink eNews
Abramson Cancer CenterNCI CANCERLIT® Search: Hodgkin's Disease - March 2002
National Cancer Institute®
Last Modified: March 1, 2002
Table of Contents
1
UI - 11697655
AU - Glaser SL; Clarke CA; Stearns CB; Dorfman RF
TI -
Age variation in Hodgkin's disease risk factors in older women: evidence
from a population-based case-control study.
SO - Leuk Lymphoma 2001 Sep-Oct;42(5):997-1004
AD - Northern California Cancer Center, Union City 94587, USA.
Hodgkin's disease (HD), which affects all age groups, has been
associated with childhood social class, particularly among adults under
age 40. Little is known about social class risk factors in older adults,
and the few existing studies have conflicting findings. As part of a
population-based case-control study of HD in women, we examined social
class risk factors by diagnostic age groups (45-54 years and 55-79
years) corresponding to incidence patterns and by histologic subtypes
based on a uniform pathologic review. Among women ages 45-54, cases were
more likely to be Catholic, to have lower income and to be taller than
controls. Among women ages 55-79, cases tended to have come from small
or large childhood households, lived in single-family childhood housing,
and had a single rather than shared bedroom at age 11. For the nodular
sclerosis (NS) histologic subtype, similar age differences in risk
factors were apparent. Comparisons between the NS and non-NS subtypes in
women ages 55-79 identified some common risk factors (single-family
childhood home, single bedroom at age 11) but others specific to one
subtype (childhood household size, adult height for NS; lower maternal
education for non-NS). Thus, some social class associations with HD
differed between middle-aged and older women, as well as between these
groups and younger adults, while others were shared across age groups.
Risk also was associated with both higher and lower childhood social
class in middle-aged and older women, in contrast with previous
findings. None of these patterns was explained entirely by histologic
subtype but may reflect age and histology subtype variation in the
HD-EBV association.
2
UI - 11554231
AU - Moschovi M; Psychou F; Menegas D; Tsangaris GT; Tzortzatou-Stathopoulou
TI -
F; Nikolaidou P
Hodgkin's disease in a child with sickle cell disease treated with
hydroxyurea.
SO - Pediatr Hematol Oncol 2001 Sep;18(6):371-6
AD - Oncology Unit, First Department of Pediatrics, University of Athens,
Agia Sophia Children's Hospital, Athens, 11527 Greece.
Hydroxyurea (HU) is an oral drug that ameliorates the clinical course of
sickle cell anemia by increasing the levels of fetal hemoglobin and
decreasing the adhesion of red cells to endothelium. Although HU has
minimal short-term toxicity, few data are available about the long-term
safety and the potential risk for carcinogenesis or leukemogenesis. An
8-year-old child with sickle cell/beta 0-thalassemia who received HU
treatment for painful crises is described. Six months after the
initiation of the HU treatment he developed Hodgkin's disease,
lymphocyte predominance subtype. Chemotherapy induced a complete
remission. After discontinuation of chemotherapy the painful crises
recurred and bone marrow transplantation was decided at the age of 12
years. Two years after the bone marrow transplantation, the child is in
complete remission without painful crises. Although the authors suggest
that the development of Hodgkin's disease is a coexisting event,
questions arise about the safety of HU treatment in childhood.
3
UI - 11554236
AU - Ragusa R; Russo S; Villari L; Schiliro G
TI -
Hodgkin's disease as a second malignant neoplasm in childhood: report of
a case and review of the literature.
SO - Pediatr Hematol Oncol 2001 Sep;18(6):407-14
AD - Department of Pediatric Hematology and Oncology, University of Catania,
Via Santa Sofia, 78 95123, Catania, Italy.
There is a known association between lymphoid malignancy and Hodgkin's
disease (HD), but the development of HD in children who have been
treated for leukemia or lymphoma is very uncommon. Hodgkin's disease is,
after retinoblastoma, the most common primary tumor that is associated
with development of second malignant neoplasm. For reasons that remain
to be determined, HD is very rare as a second malignancy [1, 2, 3]. We
report the case of a eight-year-old girl who developed HD 6 years after
treatment for common acute lymphoblastic leukemia (ALL). This case
prompted us to review the published literature for cases of secondary HD
in childhood. Our experience suggests that we should follow strictly our
patients with ALL and be ready to intervene with invasive diagnostic
procedures at the least suspicion of a second or recurrent neoplasm. The
most frequent causes of second tumors are radiotherapy, genetic
susceptibility and prior treatment with certain chemotherapeutic agents,
such as nitrogen mustards. It is likely that any type of
immunodeficiency, even without symptoms, might play a role in the
development of second tumors in childhood.
4
UI - 11843811
AU - Naumann R; Vaic A; Beuthien-Baumann B; Bredow J; Kropp J; Kittner T;
TI -
Franke WG; Ehninger G
Prognostic value of positron emission tomography in the evaluation of
post-treatment residual mass in patients with Hodgkin's disease and
non-Hodgkin's lymphoma.
SO - Br J Haematol 2001 Dec;115(4):793-800
AD - Department of Internal Medicine I, University Hospital Carl Gustav Carus
at the Dresden University of Technology, Fetscherstrasse 74, D-01307
Dresden, Germany. naumann@mk1.med.tu-dresden.de
The prognostic value of 18F-fluorodeoxyglucose (FDG) positron emission
tomography (PET) in the assessment of post-treatment residual masses in
patients with Hodgkin's disease (HD) or non-Hodgkin's lymphomas (NHL)
was evaluated. We prospectively studied 58 patients with HD (n = 43) or
NHL (n = 15) who had post-therapeutic complete remission with residual
masses (CRu) indicated by computerized tomography. Analysis of 62
residual locations by FDG-PET was performed separately for HD and NHL.
Patients with a PET-positive residual mass [standardized uptake value
(SUV) > 3] had a recurrence rate of 62.5% (5/8 patients), whereas
patients with PET-negative residual mass (SUV < or =3.0) showed a
recurrence rate of 4% (2/50 patients, P = 0.004). A positive FDG-PET
study correlated with a significantly poorer progression-free survival
(P < 0.00001). No recurrence occurred in any of the 39 HD patients with
a negative PET scan (negative predictive value, 100%). Four out of four
NHL patients with a positive PET study relapsed (positive predictive
value, 100%). In conclusion, FDG-PET is a suitable non-invasive method
with a high degree of accuracy in the prediction of early recurrence in
lymphoma patients with CRu.
5
UI - 11805358
AU - Thavaraj V; Kumar R; Arya LS
TI -
Familial Hodgkin's disease in two siblings.
SO - Indian Pediatr 2002 Jan;39(1):79-83
AD - Department of Pediatrics and Institute of Rotary Cancer Hospital, All
India Institute of Medical Sciences, New Delhi 110 029, India.
sowmyam@mantraonline.com
6
UI - 11857394
AU - Glaser SL; Clarke CA; Nugent RA; Stearns CB; Dorfman RF
TI -
Social class and risk of Hodgkin's disease in young-adult women in
1988-94.
SO - Int J Cancer 2002 Mar 1;98(1):110-7
AD - Northern California Cancer Center, Union City, CA 94587, USA.
sgkaser@nccc.org
Hodgkin's disease (HD) risk in young adults has been associated with
higher childhood social class. Although recent decades have witnessed
increases in both young-adult HD incidence rates and the socioeconomic
affluence reported to influence risk, social class risk factors have not
been reexamined. For 204 cases and 254 controls aged 19-44 years from a
population-based case-control study of HD diagnosed in 1988-94 in San
Francisco area females, we evaluated social class predictors of HD
overall and for subgroups defined by age and by ethnicity. HD was
associated weakly with a few childhood social class markers but more
strongly with combinations of these variables. Risk was higher for women
with family-owned than rented childhood homes; for US-born women with
single vs. shared bedrooms at age 11; and for women with 2+ births who
were from smaller than larger childhood households. These patterns
differed by age, with risk appearing to increase over the young-adult
years for some factors and to decrease for others. In whites, risk was
additionally associated with having a single childhood bedroom in larger
households, and with tall adult height in women from smaller childhood
households. In nonwhites, risk was higher for single bedrooms at age 11
in smaller childhood households, taller height and higher maternal
education. Most study findings support the hypothesis that HD
development in young adults follows protection from early exposure to
other children. Variation in risk by age suggests differing etiologies
across young adulthood, or the importance of birth cohort-appropriate
social-class measures. Negative findings for previously reported risk
factors may reflect their insufficient heterogeneity of exposure or
their failure to measure cohort-relevant exposures in this population.
Copyright 2001 Wiley-Liss, Inc.
7
UI - 11852730
AU - Basic-Jukic N; Basic-Koretic M; Radman I; Labar B
TI -
Reed-Sternberg cells in the pathogenesis of Hodgkin's disease.
SO - Acta Med Croatica 2001;55(3):115-21
AD - Department of Medicine, Zagreb University Hospital Center, Kispaticeva
12, 10000 Zagreb, Croatia.
Hodgkin/Reed Stemberg (HRS) cells mediate the classical features of
Hodgkin's disease. However, because of their rarity in tumor tissue,
little is known about their origin and function. Recent advances in
biotechnology, including the single cell manipulation, enabled the
insight into the biology of HRS cell. It has been demonstrated that in
the great majority of cases they are of germinal center B cell origin,
with highly developed interactive network with adjacent cells via
expression of cell adhesion molecules, tumor necrosis factor receptor
superfamily, and elaboration of different cytokines.
8
UI - 11808167
AU - Abe M
TI -
[Hodgkin's lymphoma]
SO - Nippon Rinsho 2001 Nov;59 Suppl 7():557-65
AD - Division of Pathology, Fukushima Medical University, School of Medicine.
9
UI - 11815733
AU - Skinnider BF; Kapp U; Mak TW
TI -
Interleukin 13: a growth factor in hodgkin lymphoma.
SO - Int Arch Allergy Immunol 2001 Dec;126(4):267-76
AD - Amgen Institute, Ontario Cancer Institute and the Departments of Medical
Biophysics and Immunology, University of Toronto, Toronto, Canada.
Classical Hodgkin lymphoma (cHL) is a malignant disorder of lymph nodes
with distinctive clinical and pathologic features. These features are
thought to be primarily due to the abnormal production of multiple
cytokines by the malignant cell population of HL, the Reed-Sternberg
(RS) cells. We have previously demonstrated that interleukin (IL)-13
expression is a common feature of HL and have studied its role as an
autocrine growth factor for RS cells. IL-13 and IL-13R(alpha)1, the
IL-13-specific receptor chain, are frequently expressed by HL-derived
cell lines and by RS cells from biopsy material of tissues involved by
HL. Neutralization of IL-13 in cultures of the HL-derived cell lines
HDLM-2 and L-1236 leads to a dose-dependent inhibition of proliferation,
and is associated with increased apoptosis in L-1236 cells. Signal
transducer and activator of transcription (STAT) 6 is an important
mediator of IL-13 signaling. STAT6 is constitutively activated in HL
cell lines due to autocrine secretion of IL-13. STAT6 is also
phosphorylated (P-STAT6) in RS cells from many primary HL samples,
supporting the hypothesis that IL-13 signaling occurs in these malignant
cells in vivo. Coexpression of IL-13, IL-13R(alpha)1 and P-STAT6 is
uncommon in non-Hodgkin lymphomas. Following a description of the
clinical and pathologic features of HL, this review will discuss the
function of IL-13 as an autocrine growth factor for RS cells in HL and
its potential role in mediating other features of this disease.
Copyright 2002 S. Karger AG, Basel
10
UI - 11872075
AU - Vassilakopoulos TP; Angelopoulou MK; Siakantaris MP; Kontopidou FN;
TI -
Dimopoulou MN; Barbounis A; Grigorakis V; Karkantaris C; Anargyrou K;
Chatziioannou M; Rombos J; Boussiotis VA; Vaiopoulos G; Kittas C;
Pangalis GA
Prognostic factors in advanced stage Hodgkin's lymphoma: the
significance of the number of involved anatomic sites.
SO - Eur J Haematol 2001 Nov-Dec;67(5-6):279-88
AD - Hematology Section, First Department of Internal Medicine, National and
Kapodistrian University, School of Medicine, Laikon General Hospital,
Athens, Greece.
BACKGROUND: Advanced Hodgkin's lymphoma (HL) is curable by conventional
chemotherapy in 60--70% of patients. The pretreatment identification of
a sizeable subgroup of patients with sufficiently low failure-free
survival (FFS) to be eligible for investigational treatment is
necessary. OBJECTIVES: To determine the prognostic significance of the
number of involved sites (NIS) in patients with advanced HL and its
relationship to the International Prognostic Score (IPS). METHODS: A
retrospective review of patients with advanced HL, defined as Ann Arbor
stage (AAS) IB, IIB, III or IV, treated with anthracycline-based
regimens. The end-point was FFS. RESULTS: We identified 277 patients
with a median age of 32 yr (14--78), 57% of whom were males. AAS was I
in 4% of patients, II in 29%, III in 38% and IV in 29%. B-symptoms were
recorded in 81%. Most patients had nodular sclerosis (64%) and mixed
cellularity (26%) histology. IPS was greater-than-or-equals 3 in 44% of
242 evaluable patients. The NIS was greater-than-or-equals 5 in 32% of
the patients and 20% of all patients had both greater-than-or-equals 5
involved sites and IPS greater-than-or-equals 3. The 10-yr FFS was 67%,
being 76% vs. 50% for patients with less-than-or-equals 4 vs.
greater-than-or-equals 5 involved sites (P < 0.0001). The NIS
(greater-than-or-equal 5), AAS IV and anemia were independent predictors
of FFS in multivariate analysis. The NIS remained significant along with
IPS, when the latter was included in the analysis. Patients with
greater-than-or-equals 5 involved sites and IPS greater-than-or-equals 3
had 10-yr FFS overall, and relapse-free survival of 41%, 45% and 49%,
respectively. CONCLUSIONS: The NIS was associated with FFS in advanced
HL, was independent of IPS, and led to the identification of a sizeable
subgroup of patients with 10-yr FFS of approximately 40%. This factor
should be evaluated during the development of prognostic systems.
11
UI - 11848545
AU - Yang CC; Sun SS; Lin CC; Kao CH; Lee CC
TI -
Comparison of technetium-99m tetrofosmin and gallium-67 citrate
scintigraphy for detecting malignant lymphoma.
SO - Anticancer Res 2001 Sep-Oct;21(5):3695-8
AD - Department of Urology, China Medical College Hospital, Taichung, Taiwan.
The aim of this study was to compare the value of technetium-99m
tetrofosmin (Tc-TF) scintigraphy with that of gallium-67 citrate (Ga-67)
scintigraphy for detecting malignant lymphoma. In this study, 50
patients with malignant lymphoma underwent Tc-TF and Ga-67 scintigraphy
before receiving any therapy. Tc-TF scintigraphy detected malignant
lymphoma in 44 (88%) patients, but was false-negative in 4 cases of
infradiaphragmatic malignant lymphoma and in 2 cases of malignant
lymphoma with chemotherapy resistance. Ga-67 scintigraphy detected
malignant lymphoma in 45 (90%) patients, but was false-negative in 3
cases of low-grade non-Hodgkin's lymphoma and in 2 cases of malignant
lymphoma with bone marrow involvement. There was no significant
difference in sensitivity between Tc-TF and Ga scintigraphy. However, a
combination of Tc-TF and Ga-67 scintigraphy detected malignant lymphoma
in all 50 patients (100%). We conclude that it is necessary to combine
Tc-TF and Ga-67 scintigraphy to accurately detect malignant lymphoma.
12
UI - 11602997
AU - Glatstein E
TI -
As good as it gets--training with Henry Kaplan and Saul Rosenberg during
the Stanford studies on Hodgkin's disease and lymphoma.
SO - Cancer Biother Radiopharm 2001 Aug;16(4):269-73
AD - Department of Radiation Oncology, University of Pennsylvania Health
System, 3400 Spruce Street, Philadelphia, PA 19104-4283, USA.
glatstein@xrt.upenn.edu
The Stanford team of Drs. Henry S. Kaplan and Saul A. Rosenberg churned
out an extensive amount of clinical research on the evaluation and
treatment of Hodgkin's disease and other lymphomas throughout the
1960's, 70's and 80's. After Dr. Kaplan's death in 1983, Dr. Rosenberg
continued clinical research in this area. A training experience under
these physicians was both exhilarating and productive, as the discipline
with which Drs. Kaplan and Rosenberg approached patients actually
eclipsed the individual studies which were carried out. The overall
product of their efforts, in conjunction with that of other
investigators throughout the world, changed the mindset of physicians to
approaching these patients with curative intent, rather than traditional
palliation which had been the general policy up to the late 1950's.
Today the vast majority of Hodgkin's patients who are treated get cured,
although there is still some room for further improvement. The strong
character traits of Drs. Kaplan and Rosenberg left lasting impressions,
not only on other staff, but most especially on the young trainees who
learned to accept and appreciate their efforts at excellence. Their
method of approach and the gains achieved by it became the paradigm for
the study of other malignant diseases.
13
UI - 11830608
AU - Travis LB; Gospodarowicz M; Curtis RE; Clarke EA; Andersson M; Glimelius
TI -
B; Joensuu T; Lynch CF; van Leeuwen FE; Holowaty E; Storm H; Glimelius
I; Pukkala E; Stovall M; Fraumeni JF Jr; Boice JD Jr; Gilbert E
Lung cancer following chemotherapy and radiotherapy for Hodgkin's
disease.
SO - J Natl Cancer Inst 2002 Feb 6;94(3):182-92
AD - Division of Cancer Epidemiology and Genetics, National Cancer Institute,
Bethesda, MD 20892, USA. travisl@epndce.nci.nih.gov
BACKGROUND: Lung cancer is a frequent cause of death in patients cured
of Hodgkin's disease, but the contributions of chemotherapy,
radiotherapy, and smoking are not well described. We quantified the risk
of treatment-associated lung cancer, taking into account tobacco use.
METHODS: Within a population-based cohort of 19 046 Hodgkin's disease
patients (diagnosed from 1965 through 1994), a case-control study of
lung cancer was conducted. The cumulative amount of cytotoxic drugs, the
radiation dose to the specific location in the lung where cancer
developed, and tobacco use were compared for 222 patients who developed
lung cancer and for 444 matched control patients. All statistical tests
were two-sided. RESULTS: Treatment with alkylating agents without
radiotherapy was associated with increased lung cancer risk (relative
risk [RR] = 4.2; 95% confidence interval [CI] = 2.1 to 8.8), as was
radiation dose of 5 Gy or more without alkylating agents (RR = 5.9; 95%
CI = 2.7 to 13.5). Risk increased with both increasing number of cycles
of alkylating agents and increasing radiation dose (P for trend <.001).
Among patients treated with mechlorethamine, vincristine, procarbazine,
and prednisone (MOPP), risk increased with cumulative amounts of
mechlorethamine and procarbazine (P<.001) when evaluated separately.
Statistically significantly elevated risks of lung cancer were apparent
within 1-4 years after treatment with alkylating agents, whereas excess
risk after radiotherapy began 5 years after treatment and persisted for
more than 20 years. Risk after treatment with alkylating agents and
radiotherapy together was as expected if individual excess risks were
summed. Tobacco use increased lung cancer risk more than 20-fold; risks
from smoking appeared to multiply risks from treatment. CONCLUSIONS:
Past treatments with alkylating agents and radiation therapy for
Hodgkin's disease were associated with an increased risk of lung cancer
in a dose-dependent and additive fashion. The precise risk estimates,
however, should be interpreted cautiously, given the possible residual
and enhancing effects of tobacco.
14
UI - 11760650
AU - Engel R
TI -
[Diagnostic difficulties in the discernment of lymphogranulomatosis.
1926]
SO - Orv Hetil 2001 Oct 21;142(42):2317-21
15
UI - 11786576
AU - Ferme C; Mounier N; Divine M; Brice P; Stamatoullas A; Reman O; Voillat
TI -
L; Jaubert J; Lederlin P; Colin P; Berger F; Salles G
Intensive salvage therapy with high-dose chemotherapy for patients with
advanced Hodgkin's disease in relapse or failure after initial
chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte
H89 Trial.
SO - J Clin Oncol 2002 Jan 15;20(2):467-75
AD - Groupe d'Etudes des Lymphomes de l'Adulte, Hopital Saint-Louis, Paris,
France. ferme@igr.fr
PURPOSE: To evaluate prospectively the feasibility and efficacy of early
intensive therapy, including intensified cytoreductive chemotherapy (CT)
and high-dose CT (HDCT) followed by autologous stem-cell transplantation
(ASCT), in patients with advanced Hodgkin's disease (HD) who failed to
respond completely or relapsed after initial treatment. PATIENTS AND
METHODS: Among 533 eligible patients with newly diagnosed stage IIIB-IV
HD enrolled in the H89 trial, all 157 patients with induction failure
(IF) (n = 67), partial response (PR) of less than 75% (n = 22), or
relapse (n = 68) were included in this study. Planned salvage therapy
included mitoguazone, ifosfamide, vinorelbine, and etoposide monthly for
two to three cycles followed by high-dose carmustine, etoposide,
cytarabine, and melphalan with ASCT. RESULTS: With a median follow-up of
50 months, the 5-year survival estimates were 30%, 72%, and 76% for the
IF, PR, and relapse groups, respectively (P =.0001), 71% for the 101
patients given HDCT, and 32% for the 48 patients treated without HDCT (P
=.0001). Multivariate analysis using time-dependent Cox model indicated
that B symptoms at progression, salvage without HDCT, and chemoresistant
disease before HDCT were significantly associated with shorter overall
survival. CONCLUSION: Early intensive therapy improves the outcomes of
patients with advanced HD who failed to respond completely to initial
treatment and those who relapsed with adverse prognostic factors.
However, for patients with IF and chemoresistant disease, this approach
remains unsatisfactory.
16
UI - 11786577
AU - Sieber M; Tesch H; Pfistner B; Rueffer U; Lathan B; Brosteanu O; Paulus
TI -
U; Koch T; Pfreundschuh M; Loeffler M; Engert A; Josting A; Wolf J;
Hasenclever D; Franklin J; Duehmke E; Georgii A; Schalk KP; Kirchner H;
Doelken G; Munker R; Koch P; Herrmann R; Greil R; Anselmo AP; Diehl V
Rapidly alternating COPP/ABV/IMEP is not superior to conventional
alternating COPP/ABVD in combination with extended-field radiotherapy in
intermediate-stage Hodgkin's lymphoma: final results of the German
Hodgkin's Lymphoma Study Group Trial HD5.
SO - J Clin Oncol 2002 Jan 15;20(2):476-84
AD - German Hodgkin's Lymphoma Study Group, Cologne, Germany.
markus.sieber@medizin.uni-koeln.de
PURPOSE: To investigate whether treatment results in intermediate-stage
Hodgkin's lymphoma can be improved by rapid application of
non-cross-resistant drugs, the 10-drug regimen cyclophosphamide,
vincristine, procarbazine, and prednisone (COPP), doxorubicin,
bleomycin, and vinblastine (ABV), and ifosfamide, methotrexate,
etoposide, and prednisone (IMEP), repeated every 6 weeks, was compared
with conventional alternating COPP/doxorubicin, bleomycin, vinblastine,
and dacarbazine (ABVD) administered every 8 weeks. PATIENTS AND METHODS:
Hodgkin's lymphoma with at least one risk factor (massive mediastinal
tumor, massive spleen involvement, extranodal disease, elevated ESR, or
more than two lymph node areas involved) and all patients in stage IIIA
Hodgkin's lymphoma were randomized to receive two cycles of COPP/ABVD or
COPP/ABV/IMEP followed by extended-field radiotherapy. RESULTS: Both
regimens produced similar rates for treatment responses (complete
remission, 93% v 94%), freedom from treatment failure (80% v 79%), and
overall survival (88% for both regimens) at a median follow-up time of 7
years. Most serious toxicities during chemotherapy were similar in both
regimens. However, World Health Organization grade 3 and 4
leukocytopenia occurred significantly more frequently in the
COPP/ABV/IMEP arm (53% v 44% of patients; P =.010). There were no
differences in the number of serious infections and toxic deaths during
therapy. The number of second malignancies was also the same in both
arms (22 each). CONCLUSION: Alternating COPP/ABVD and rapid alternating
COPP/ABV/IMEP in combination with extended-field radiotherapy are
equally effective in intermediate-stage Hodgkin's lymphoma and produce
excellent long-term treatment results.
17
UI - 11839579
AU - Aldinucci D; Poletto D; Gloghini A; Nanni P; Degan M; Perin T; Ceolin P;
TI -
Rossi FM; Gattei V; Carbone A; Pinto A
Expression of functional interleukin-3 receptors on Hodgkin and
Reed-Sternberg cells.
SO - Am J Pathol 2002 Feb;160(2):585-96
AD - Clinical & Experimental Hematology Research Unit, Centro di Riferimento
Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS),
Istituto Nazionale Tumori, via Pedemontana Occidentale 12, Aviano
I-33081, Italy. daldinucci@cro.it
The human interleukin-3 receptor (IL-3R) is a heterodimeric complex
consisting of an IL-3-specific alpha chain (IL-3Ralpha) and a common
beta chain (beta(c)), this latter shared with the receptors for
granulocyte-macrophage colony-stimulating factor and IL-5. Despite
extensive research on cytokine circuitries regulating proliferation and
survival of tumor cells in Hodgkin's disease (HD) the functional
expression of IL-3Rs in this pathobiological entity has not yet been
investigated. In the present study, we demonstrate that the great
majority (>90%) of malignant Hodgkin and Reed-Sternberg cells of classic
HD (19 of 19 analyzed cases) express IL-3Ralpha by immunostaining of
frozen sections and cell suspensions from involved lymph nodes.
Accordingly, HD cell lines (L428, KMH2, HDLM2, L1236) expressed the
alpha and beta chains of IL-3R both at the mRNA and protein level, with
a molecular size of IL-3Ralpha identical (70 kd) to that expressed by
human myeloid cells. Exogenous IL-3 promoted the growth of cultured
Hodgkin and Reed-Sternberg cells, such effect being potentiated by IL-9
co-stimulation, and was able to partially rescue tumor cells from
apoptosis induced by serum deprivation. This data suggests an
involvement of IL-3/IL-3R interactions in the cellular growth of HD
through paracrine mechanisms.
18
UI - 11844834
AU - Weekes CD; Vose JM; Lynch JC; Weisenburger DD; Bierman PJ; Greiner T;
TI -
Bociek G; Enke C; Bast M; Chan WC; Armitage JO; Nebraska Lymphoma Study
Group
Hodgkin's disease in the elderly: improved treatment outcome with a
doxorubicin-containing regimen.
SO - J Clin Oncol 2002 Feb 15;20(4):1087-93
AD - University of Nebraska Medical Center, Omaha, NE 68198-7680, USA.
jmvose@unmc.edu
PURPOSE: Hodgkin's disease (HD) is a malignancy that displays a bimodal
age distribution. Previous reports of treatment in patients
greater-than-or-equal 60 years have found a poor outcome, particularly
in patients with advanced disease. Because of an improved side-effect
profile, the regimen of chlorambucil, vinblastine, procarbazine, and
prednisone (ChlVPP) has been proposed for use in elderly patients.
previously untreated HD received either ChlVPP (n = 176) or ChlVPP plus
doxorubicin/bleomycin/vincristine (ChlVPP/ABV hybrid; n = 86). Fifty-six
patients were greater-than-or-equal 60 years old, and 206 were younger
than 60 years. RESULTS: The 5-year overall survival (OS; 87% v 39%) and
the 5-year event-free survival (EFS; 75% v 31%) favored patients younger
than 60 years of age. Prognostic factors analyzed in patients
greater-than-or-equal 60 years of age, other than type of therapy,
included sex, stage, Karnofsky performance score, lactic dehydrogenase,
number of extranodal sites, B symptoms, size of largest mass, and
histologic subtype. In patients older than 60 years, none of the
clinical features was a statistically significant predictor of EFS;
however, ChlVPP/ABV hybrid was associated with a decreased risk of an
event (relative risk, 0.40; 95% confidence interval, 0.19 to 0.83; P
=.014) compared with ChlVPP. The 5-year OS for patients
greater-than-or-equal 60 years who received ChlVPP was 30%, compared
with 67% for those patients receiving the ChlVPP/ABV regimen (P =.0086)
CONCLUSION: Patients greater-than-or-equal 60 years with HD who require
chemotherapy are better treated with ChlVPP/ABV hybrid than with ChlVPP
alone.
19
UI - 11758105
AU - Tez M; Keskek M
TI -
Is needle biopsy of the liver necessary in staging laparotomy?
SO - Acta Chir Belg 2001 Sep-Oct;101(5):224-5
AD - Department of General Surgery, Hacettepe University Faculty of Medicine,
Ankara 06100, Turkey.
The purpose of this retrospective study was to examine the necessity of
needle biopsy in staging laparotomy. Between 1988 and 1998, 31 patients
diagnosed with Hodgkin's disease underwent staging laparotomy. All
patients had lymph node sampling from perihilar, coeliac, periaortic and
iliac regions, splenectomy, wedge biopsy of the liver as well as tru-cut
needle biopsies from both liver lobes. Two patients (6.5%) had hepatic
involvement of the liver detected by both wedge and needle biopsies. In
the remaining patients, all biopsies of the liver obtained by either
method were negative. These findings strongly suggest that wedge biopsy
of the liver provides sufficient information for the diagnosis and there
is no need for tru-cut biopsy which has its own complications.
20
UI - 11847030
AU - Eghbali H; Soubeyran P; Soubeyran I; Monnerau A; Cazorla S
TI -
[Update on lymphomas]
SO - Bull Cancer 2002 Jan;89(1):89-99
AD - Service d'hematologie-oncologie, Institut Bergonie, Centre regional de
lutte contre le cancer, 229, cours de l'Argonne, 33076 Bordeaux Cedex.
Important progress have been recently achieved in the management of
Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL). Prognostic
factors are now better defined in HD thanks to new biologic and
radiologic information which complete old and relevant clinical factors.
These parameters are expected to improve decision making in patient's
management. However, treatment strategy is under new discussion and
controversies about the role of radiotherapy and its doses. There are
now enough arguments to consider radiotherapy unnecessary in advanced
stages when a complete remission is achieved by chemotherapy. There is
also important concern about late effects of treatment and not only
secondary cancers. Non-Hodgkin's lymphomas are heterogeneous and
different entities are now better defined and described, thanks to a
common and similar language for immunological clinical data and
treatment outcome. New strategies are under investigation using
monoclonal antibodies with or without radioisotopes, in association with
chemotherapy or radiotherapy. Undoubtedly, these new approaches are
going to improve the overall prognosis of NHL.
21
UI - 11713590
AU - Low SE; Horsman JM; Hancock H; Walters SJ; Hancock BW
TI -
Prognostic markers in malignant lymphoma: an analysis of 1,198 patients
treated at a single centre.
SO - Int J Oncol 2001 Dec;19(6):1203-9
AD - YCR Department of Clinical Oncology, Weston Park Hospital, Sheffield,
UK.
The prognostic significance of 20 putative markers has been assessed in
a consecutive series of 1,198 patients with malignant lymphoma seen by
the Sheffield Lymphoma Group over three decades. Univariate analysis
disclosed that ten factors for both Hodgkin's disease (HD) and
non-Hodgkin's lymphoma (NHL) Grade I, and twelve factors for NHL Grade
II had prognostic significance. However, multivariate analysis selected
only three (age, serum albumin and lymphocyte count) for HD, one (serum
albumin) for NHL Grade I and five (age, stage, erythrocyte sedimentation
rate, serum albumin and serum lactate dehydrogenase) for NHL Grade II as
independent predictors for survival. Risk adjusted prognostic models
were derived for Hodgkin's disease and NHL Grade II. For Hodgkin's
disease the presence of 3 risk factors predicted for only 35% long-term
survival for this group of patients. For NHL Grade II the group with 3-5
risk factors present had a median survival of less than 2 years compared
to a 9-year median survival in patients with 1 risk factor present.
Whilst these models are being validated on a larger series of patients
and will also be tested prospectively, new markers are needed to
facilitate decisions on treatment for individual patients.
22
UI - 11841433
AU - Fend F; Martinez A; Quintanilla-Martinez L; Sanz L; Combalia N; Raffeld
TI -
M; Jaffe ES; Montserrat E; Campo E
Clonally unrelated Hodgkin's disease following autologous stem cell
transplant for B-cell lymphoma.
SO - Br J Haematol 2002 Feb;116(2):329-33
AD - Department of Pathology, Technical University Munich and GSF National
Research Center for Environment and Health Neuherberg, Munich, Germany.
fend@lrz.tum.de
Lymphoproliferative disorders after autologous stem cell transplantation
(SCT) are rare. We describe two cases of Hodgkin's disease (HD) as a
late secondary neoplasia following autologous SCT for mantle cell
lymphoma and B-cell chronic lymphocytic leukaemia respectively. Both HD
cases were of mixed cellularity type, showed Epstein-Barr virus (EBV)
positivity and followed an aggressive course. Clonal analysis of
rearranged immunoglobulin genes from the primary B-cell neoplasm and the
secondary HD provided evidence of separate clonal origins of the two
tumours in both patients, thus excluding secondary transformation of the
original B-cell clone through EBV as the causative event for development
of HD.
23
UI - 11721380
AU - Yong W
TI -
[Trends in the therapy of Hodgkin's disease]
SO - Zhonghua Xue Ye Xue Za Zhi 1999 Nov;20(11):608-9
24
UI - 11821436
AU - Canellos GP
TI -
New treatments for advanced Hodgkin's disease: an uphill fight beginning
close to the top.
SO - J Clin Oncol 2002 Feb 1;20(3):607-9
25
UI - 11821442
AU - Horning SJ; Hoppe RT; Breslin S; Bartlett NL; Brown BW; Rosenberg SA
TI -
Stanford V and radiotherapy for locally extensive and advanced Hodgkin's
disease: mature results of a prospective clinical trial.
SO - J Clin Oncol 2002 Feb 1;20(3):630-7
AD - Department of Medicine, Division of Medical Oncology, Stanford
University Medical Center, Stanford, CA 94304, USA.
sandra.horning@stanford.edu
PURPOSE: To provide more mature data on the efficacy and complications
of a brief, dose-intense chemotherapy regimen plus radiation therapy
(RT) to bulky disease sites for locally extensive and advanced-stage
Hodgkin's disease. PATIENTS AND METHODS: One hundred forty-two patients
with stage III or IV or locally extensive mediastinal stage I or II
Hodgkin's disease received Stanford V chemotherapy for 12 weeks followed
by 36-Gy RT to initial sites of bulky (> or =5 cm) or macroscopic
splenic disease. Freedom from progression (FFP), overall survival (OS),
and freedom from second relapse (FF2R) were determined using life-table
estimates. Outcomes were analyzed according to the international
prognostic score. Late effects of treatment were recorded in follow-up.
RESULTS: With a median follow-up of 5.4 years, the 5-year FFP was 89%
and the OS was 96%. No patient progressed during treatment, and there
were no treatment-related deaths. FFP was significantly superior among
patients with a prognostic score of 0 to 2 compared with those with a
score of 3 and higher (94% v 75%, P <.0001). No secondary leukemia was
observed. To date, there have been 42 pregnancies after treatment. Among
16 patients who relapsed, the FF2R was 69% at 5 years. CONCLUSION: These
data confirm our preliminary report that Stanford V chemotherapy with RT
to bulky disease sites is highly effective in locally extensive and
advanced Hodgkin's disease. It is most important to compare this
approach with standard doxorubicin, bleomycin, vinblastine, and
dacarbazine chemotherapy in the ongoing intergroup trial (E2496) to
determine whether Stanford V with or without RT represents a therapeutic
advance.
26
UI - 11893364
AU - Wirth A; Seymour JF; Hicks RJ; Ware R; Fisher R; Prince M; MacManus MP;
TI -
Ryan G; Januszewicz H; Wolf M
Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67
scintigraphy, and conventional staging for Hodgkin's disease and
non-Hodgkin's lymphoma.
SO - Am J Med 2002 Mar;112(4):262-8
AD - Division of Radiation Oncology, Peter McCallum Cancer Institute, East
Melbourne, Victoria, Australia.
PURPOSE: To compare fluorine-18 fluorodeoxyglucose positron emission
tomography (PET) and gallium scanning with each other and with
conventional staging, for patients with Hodgkin's disease or
non-Hodgkin's lymphoma. SUBJECTS AND METHODS: Fifty patients had PET,
gallium scanning, and conventional staging of newly diagnosed or
progressive Hodgkin's disease or non-Hodgkin's lymphoma. Disease sites,
stage, and treatment plans were assessed retrospectively. RESULTS:
Positron emission tomography and gallium scanning each upstaged 14% of
patients (n = 7). Management was altered by PET in 9 cases (18%) and by
gallium scanning in 7 (14%, P = 0.6). Disease was evident in 117 sites
in 42 patients. The case positivity rate for conventional assessment was
90%; for PET, 95%; for gallium scanning, 88%; for conventional
assessment plus PET, 100%; and for conventional assessment plus gallium
scanning, 98%. Site positivity rates for conventional assessment were
68%; for PET, 82%; for gallium scanning, 69% (conventional vs. PET, P =
0.01; conventional vs. gallium scanning, P = 0.9; PET vs. gallium
scanning, P = 0.01); for conventional assessment plus PET, 96%; and for
conventional assessment plus gallium scanning, 94%. Positron emission
tomography and gallium scanning were entirely concordant in 31 patients;
in the other 19 patients, PET identified 25 sites missed by gallium
scanning, whereas gallium scanning identified 10 sites missed by PET.
CONCLUSION: In this retrospective study, PET demonstrated a higher site
positivity rate than did gallium scanning, with similar case positivity
rates. These data support the use of PET in place of gallium scanning
for the staging of patients with Hodgkin's disease or non-Hodgkin's
lymphoma.
27
UI - 11893371
AU - Talbot TR
TI -
Cases from the Osler Medical Service at Johns Hopkins University.
Hodgkin's disease with Pel-Ebstein fevers.
SO - Am J Med 2002 Mar;112(4):312-3
28
UI - 11893374
AU - Kaplan LD
TI -
Fluorine-18 fluorodeoxyglucose positron emission tomography for
lymphoma: incorporating new technology into clinical care.
SO - Am J Med 2002 Mar;112(4):320-1
The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
